MAPT and Alzheimer disease: Moreover, since TBI is recognized as a major risk factor for Alzheimer’s disease (AD), an interesting study by Sawmiller and colleagues performed on Tg2576 mice overexpressing Amyloid β (Aβ) protein as a model system for AD, showed that significant increases in Aβ deposition, glycogen synthase-3 (GSK-3) activation, and phospho-tau protein levels observed 3 days after TBI can be successfully ameliorated by 15 days of luteolin pre-treatment [81].